Scopus Biopharma Inc
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3s… Read more
Scopus Biopharma Inc (SCPS) - Net Assets
Latest net assets as of June 2023: $-10.50 Million USD
Based on the latest financial reports, Scopus Biopharma Inc (SCPS) has net assets worth $-10.50 Million USD as of June 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($497.55K) and total liabilities ($11.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-10.50 Million |
| % of Total Assets | -2111.24% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 85.27 |
Scopus Biopharma Inc - Net Assets Trend (2017–2022)
This chart illustrates how Scopus Biopharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Scopus Biopharma Inc (2017–2022)
The table below shows the annual net assets of Scopus Biopharma Inc from 2017 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-7.06 Million | -275.79% |
| 2021-12-31 | $4.02 Million | +319.39% |
| 2020-12-31 | $-1.83 Million | -2110.05% |
| 2019-12-31 | $-82.86K | -1455.75% |
| 2018-12-31 | $-5.33K | -105.24% |
| 2017-12-31 | $101.59K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scopus Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5280144100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $21.09K | % |
| Other Comprehensive Income | $-4.95K | % |
| Other Components | $46.48 Million | % |
| Total Equity | $-6.56 Million | 100.00% |
Scopus Biopharma Inc Competitors by Market Cap
The table below lists competitors of Scopus Biopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Atesco Industrial Cartering JSC
VN:ATS
|
$10.27K |
|
FAN MILK LTD.
GSE:FML
|
$10.27K |
|
Pamtek Co. Ltd.
KO:271830
|
$10.28K |
|
RoboGroup T.E.K. Ltd
PINK:ROBOF
|
$10.28K |
|
Otsuka Pakistan Ltd
KAR:OTSU
|
$10.26K |
|
46IE
LSE:46IE
|
$10.25K |
|
TAYLOR WIMPEY - Dusseldorf Stock Exchang
DU:TWW
|
$10.25K |
|
Chykingyoung Investment Development Holdings Inc
PINK:CHYI
|
$10.23K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scopus Biopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 4,017,449 to -6,564,330, a change of -10,581,779 (-263.4%).
- Net loss of 11,609,827 reduced equity.
- Other comprehensive income increased equity by 81,699.
- Other factors increased equity by 946,349.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.61 Million | -176.86% |
| Other Comprehensive Income | $81.70K | +1.24% |
| Other Changes | $946.35K | +14.42% |
| Total Change | $- | -263.40% |
Book Value vs Market Value Analysis
This analysis compares Scopus Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.01 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $-0.01 | $0.00 | x |
| 2020-12-31 | $-0.14 | $0.00 | x |
| 2021-12-31 | $0.23 | $0.00 | x |
| 2022-12-31 | $-0.31 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scopus Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-126.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-685.43K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.68 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.39 Million |
| 2021 | -634.67% | 0.00% | 0.00x | 2.04x | $-25.90 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.95 Million |
Industry Comparison
This section compares Scopus Biopharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scopus Biopharma Inc (SCPS) | $-10.50 Million | 0.00% | N/A | $10.27K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |